Academic genomics laboratories, hospitals and clinics, and pharmaceutical and biotechnology companies are the main buyers of next generation sequencing, and what they purchase is a bundle: instruments, library preparation and target enrichment kits, consumables, and the software and services that turn raw reads into a result. Public health and reproductive health screening programs buy from the same shelf. Contrive Datum Insights has published its Next Generation Sequencing Market study covering 2026-2034, and it sizes the global market at USD 14.51 billion in 2025.
The study projects growth from USD 16.61 billion in 2026 to USD 49.09 billion by 2034, a compound annual growth rate of 14.5% across the forecast period. Declining per-sample sequencing cost is the largest single contributor to that growth, and the study rates its impact high.
Where Buyers Are Putting Their Money
By end user, Academic & Research Institutes led in 2025 with 35.01% of revenue at USD 5.08 billion. Hospitals & Clinics is the faster mover at 16.15%, a sign that routine clinical use is pulling spending away from the research bench over time.
By product, Consumables is the largest line, with 37.97% of 2025 revenue at USD 5.51 billion. It grows at 13.06%, a little under the market's 14.5%. Data Analysis is the opposite case: it compounds at 20.26%, the fastest of any product line, lifting its share of revenue from 13.99% to 22% and its value from USD 2.03 billion to USD 10.8 billion. Buyers who once treated analysis as an afterthought are now budgeting for it.
The other cuts tell a similar story. By technology, WGS led in 2025 with 29.98% of revenue at USD 4.35 billion. By application, Oncology led with 16.61% at USD 2.41 billion, while Newborn Genetic Screening grows fastest at 19.77%. By workflow, NGS Library Preparation Kits led with 19.99% at USD 2.9 billion, and Automated Library Preparation grows fastest at 18.86%.
Geographically, North America leads with 41.97% of 2025 revenue, worth USD 6.09 billion, and reaches USD 18.66 billion by 2034. Asia Pacific takes a rising share, from 21.99% in 2025 to 26.99% in 2034, as its revenue grows from USD 3.19 billion to USD 13.25 billion. Middle East and Africa remains the smallest region throughout, at 5.03% of 2025 revenue and 4.99% by 2034. The United States is the largest single country market at USD 5.18 billion in 2025, or 35.7% of global revenue.
The growth outlook depends on how fast the cost of a run falls and how widely payers cover it. In the study's bull case, sequencing reagent costs fall faster than the base case and companion diagnostics reimbursement reaches more markets sooner, which would take 2034 revenue to USD 56.45 billion. In the bear case, reagent and consumables pricing stays firmer than expected and reimbursement for companion diagnostics and NIPT slows in major markets, holding 2034 revenue to USD 42.71 billion. The base case sits at USD 49.09 billion.
The report segments the market across five axes (product, technology, application, workflow and end user), with revenue and a growth rate for every line in every year from 2020 to 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind each estimate. It is delivered as a PDF, and a free sample is available on request.